Tecarfarin

Drug Profile

Tecarfarin

Alternative Names: ATI-5000; ATI-5923

Latest Information Update: 17 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ARYx Therapeutics
  • Developer Armetheon
  • Class Anticoagulants; Small molecules
  • Mechanism of Action Vitamin K epoxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Thromboembolism; Thrombosis

Most Recent Events

  • 30 Mar 2017 Armetheon announces intention to submit NDA to US FDA in the year 2019
  • 14 Feb 2017 Phase-III clinical trials in Thrombosis (Prevention) in USA (PO) before February 2017 (Armetheon Pipeline, February 2017)
  • 14 Feb 2017 The European Medicines Agency Scientific Advice Working Group advises that Armetheon conduct a pivotal phase III trial for Thromboembolism and Thrombosis (Prevention)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top